We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

13% more capital invested

Capital invested by funds: $354M → $399M (+$44.8M)

6% more funds holding

Funds holding: 116 → 123 (+7)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $4.37M

Holders
123
Holders Change
+7
Holders Change %
+6.03%
% of All Funds
3.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
36
Reduced
38
Closed
12
Calls
$3.06M
Puts
$4.37M
Net Calls
-$1.31M
Net Calls Change
-$776K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$7.06M
2
Millennium Management
Millennium Management
New York
+$3.28M
3
BFA
BlackRock Fund Advisors
California
+$1.92M
4
Morgan Stanley
Morgan Stanley
New York
+$1.65M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$1.48M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.82M
2
State Street
State Street
Massachusetts
-$3.63M
3
PI
Putnam Investments
Massachusetts
-$3.54M
4
CWG
C WorldWide Group
Denmark
-$2.68M
5
SFM
Sphera Funds Management
Israel
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$151M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$38.4M +$802K +146,770 +2%
ACM
3
Abrams Capital Management
Massachusetts
$33.5M – – –
State Street
4
State Street
Massachusetts
$17M -$3.63M -665,039 -19%
BIT
5
BlackRock Institutional Trust
California
$15.4M +$173K +31,625 +1%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$14.5M -$3.82M -698,500 -22%
BFA
7
BlackRock Fund Advisors
California
$13.9M +$1.92M +350,552 +17%
Ameriprise
8
Ameriprise
Minnesota
$10.7M -$524K -95,854 -5%
Norges Bank
9
Norges Bank
Norway
$9.97M – – –
Bank of New York Mellon
10
Bank of New York Mellon
New York
$8.12M +$1.48M +270,318 +24%
RHJA
11
Rice Hall James & Associates
California
$7.62M -$136K -24,924 -2%
DM
12
Deerfield Management
New York
$7.57M +$7.06M +1,291,531 New
Northern Trust
13
Northern Trust
Illinois
$5.61M +$26.9K +4,926 +0.5%
Millennium Management
14
Millennium Management
New York
$5.02M +$3.28M +599,504 +233%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.4M +$150K +27,501 +4%
Goldman Sachs
16
Goldman Sachs
New York
$3.85M +$205K +37,554 +6%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$2.92M +$889K +162,734 +48%
Morgan Stanley
18
Morgan Stanley
New York
$2.68M +$1.65M +302,403 +195%
RPAM
19
Rhenman & Partners Asset Management
Sweden
$2.49M -$410K -75,000 -15%
Charles Schwab
20
Charles Schwab
California
$2.41M +$132K +24,133 +6%
Boston Partners
21
Boston Partners
Massachusetts
$2.4M – – –
BIM
22
BlackRock Investment Management
Delaware
$1.73M -$4.96K -908 -0.3%
Group One Trading
23
Group One Trading
Illinois
$1.57M -$106K -19,342 -7%
RA
24
Royce & Associates
New York
$1.5M -$333K -61,000 -19%
UBS Group
25
UBS Group
Switzerland
$1.38M -$304K -55,585 -19%
1
2 3 4 5

KERX Hedge Fund Activity: Q4 2016 in Review

123 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 13% from $354M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.

  • 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
  • Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 13% quarter-over-quarter.
  • 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2016.